^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Breyanzi (lisocabtagene maraleucel)

    i
    Other names: anti-CD19/EGFRt/4-1BB/zeta modified CAR CD8+ and CD4+ T lymphocyte therapy, JCAR 017, liso-cel, JCAR-017, JCAR017, anti-CD19-EGFRt-4-1BB-zeta modified CAR CD8+ and CD4+ T lymphocyte therapy, CD19-CAR T cell immunotherapy, CD19 specific CAR T cells also expressing an EGFRt
    Company:
    BMS
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    4d
    Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group. (PubMed, Hemasphere)
    We conducted a multicenter retrospective study using the French DESCAR-T registry, including patients with LBCL who relapsed after 2L CAR T-cell therapy with axicabtagene ciloleucel or lisocabtagene maraleucel. This study represents the first real-world analysis of outcomes after relapse following 2L CAR T-cell therapy. Despite the more frequent incorporation of BsAbs into the therapeutic landscape, overall prognosis and treatment efficacy remain dismal, highlighting the urgent need for innovative therapeutic strategies and dedicated prospective trials in this emerging double-refractory population.
    Journal
    |
    CRP (C-reactive protein)
    |
    Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel)
    10d
    Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=20, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • nemtabrutinib (MK-1026)
    10d
    Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=10, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • Minimal residual disease
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Foresight CLARITY™
    |
    Breyanzi (lisocabtagene maraleucel)
    15d
    Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy. (PubMed, J Clin Oncol)
    Liso-cel achieved deeper, more durable molecular clearance by ctDNA, consistent with superior EFS and PFS versus ASCT for second-line LBCL treatment. ctDNA-MRD provided prognostic value beyond PET, supporting its role as a complementary biomarker for treatment response and relapse prediction.
    Journal • Circulating tumor DNA
    |
    PhasED-Seq™ ctDNA assay
    |
    Breyanzi (lisocabtagene maraleucel)
    19d
    The Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients with Indolent Lymphoma (ChiCTR2600121485)
    P4, N=75, Henan Cancer Hospital; Henan Cancer Hospital
    New P4 trial
    |
    Breyanzi (lisocabtagene maraleucel) • lisaftoclax (APG-2575)
    1m
    Impaired hematopoiesis affects apheresis and CAR T-cell product composition and treatment response. (PubMed, Transfusion)
    These findings highlight the importance of early leukapheresis, ideally before intensive treatments, to optimize T-cell yield, product quality, and therapeutic efficacy.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • HD-CAR-1
    1m
    Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Fred Hutchinson Cancer Center | Initiation date: Apr 2026 --> Jul 2026
    Trial initiation date
    |
    cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • nemtabrutinib (MK-1026)
    1m
    Current Treatment of Double Refractory Chronic Lymphocytic Leukemia: A Focus on Novel Drugs. (PubMed, Clin Lymphoma Myeloma Leuk)
    Noncovalent BTK inhibitors, particularly pirtobrutinib, has shown impressive activity in patients who have progressed on covalent BTKi. The FDA approval of lisocabtagene maraleucel represents a significant milestone in the treatment of double refractory CLL, providing a potentially curative option for eligible patients. The development of effective treatments for double refractory CLL represents an urgent unmet clinical need and the promising results from emerging therapies offer hope for improved outcomes in this challenging patient population.
    Review • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Breyanzi (lisocabtagene maraleucel) • Jaypirca (pirtobrutinib)
    2ms
    LTFU: Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (clinicaltrials.gov)
    P2/3, N=312, Recruiting, Celgene | N=214 --> 312
    Enrollment change
    |
    Breyanzi (lisocabtagene maraleucel) • Abecma (idecabtagene vicleucel)
    2ms
    A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma (clinicaltrials.gov)
    P2, N=65, Recruiting, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
    Trial initiation date
    |
    Rituxan (rituximab) • temozolomide • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • leucovorin calcium • fludarabine IV • Matulane (procarbazine hydrochloride)
    2ms
    A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov)
    P3, N=0, Withdrawn, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | N=300 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Breyanzi (lisocabtagene maraleucel) • bendamustine • fludarabine IV
    3ms
    CA082-1215: Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) as First-Line Therapy in Adults with Transplant-Ineligible Primary Central Nervous System Lymphoma (2025-521144-38-00)
    P1/2, N=31, Recruiting, Bristol-Myers Squibb Services Unlimited Company
    New P1/2 trial
    |
    Rituxan (rituximab) • temozolomide • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • leucovorin calcium • fludarabine IV • Matulane (procarbazine hydrochloride) • Actemra IV (tocilizumab)